Journal of Medicinal Chemistry · 1990 · 64 citations · 0 references
Life SciencesMedicinal ChemistryPharmacologyBiochemical PharmacologyMolecular PharmacologyStructure-activity RelationshipsCholesterol BiosynthesisCholesterol MetabolismEnzyme InhibitionLipid BiosynthesisLipid Biosynthesis InhibitionCholesterol Biosynthesis ControlPharmacological Inhibition Of Cholesterol BiosynthesisPyrazole ChemistrySterol Biosynthesis Inhibition
A series of 1,3,5-trisubstituted pyrazole mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Since previous studies suggested that the 5-(4-fluorophenyl) and 3-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations in position 1 of the pyrazole ring. Biological evaluation of analogues bearing a variety of 1-substituents suggested that, although most substituents were tolerated, none afforded an advantage over phenyl, which exhibited potency comparable to that of compactin in vitro.